Emphasis on Product Type (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, and Others); Indication (Oncology, Hematology, Renal Diseases, and Others); and Region/Country
The Global Erythropoietin Stimulating Agent Market was valued at USD 8.3 Billion in 2022 and is expected to grow a CAGR of 8.6% during the forecast period (2023-2030). Erythropoietin stimulating agents (ESAs) are drugs that boost red blood cell production, commonly used to address anemia in conditions like chronic kidney disease or cancer. They work similarly to the natural hormone erythropoietin, stimulating red blood cell formation in the bone marrow. However, their usage needs careful monitoring due to potential side effects like increased risk of blood clots or elevated blood pressure. Erythropoietin stimulating agents are mainly used in cases of acute blood deficiency or anemia which might occur due to several chronic conditions including kidney disorder, cancer, and others. Also, anemia is mainly gaining prominence due to the increased consumption of alcohol and tobacco. According to the University of Texas’s MD Anderson Cancer Center, anemia is a common condition in cancer patients.
Insights Presented in the Report
“Amongst product type, darbepoetin-alfa category to witness higher CAGR during the forecast period”
Based on product type, the market is segmented into epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. The darbepoetin-alfa segment is expected to grow with a high CAGR during the forecast period as it has a longer half-life in the human body, allowing for less frequent dosing compared to some other medications. It’s a synthetic form of erythropoietin, a hormone that stimulates the production of red blood cells in the bone marrow which is used to treat anemia, particularly in patients with chronic kidney disease or those undergoing chemotherapy. A diet lacking in fruits and vegetables, an increasing geriatric population, and a rising number of anemic patients are boosting its growth in the market. For instance, according to the Institute for Health Metrics and Evaluation in July 2023, one-fourth of the global population is estimated to be anemic in the coming years, with cases increasing rapidly for women, expectant mothers, young girls, and children younger than age 5. Thus, the darbepoetin-alfa category is expected to witness a higher CAGR during the forecast period.
“Amongst indication, oncology held a significant share in the market in 2022”
Based on indication, the market is categorized into oncology, hematology, renal diseases, and others. The bioinformatics segment is dominating the market owing to the rising cases of cancer globally. For instance, according to the World Cancer Research Fund International, there were more than 1.4 million new cases of prostate cancer in 2020. Oncology-related anemia refers to a condition where a person diagnosed with cancer experiences a lower-than-normal level of red blood cells due to the cancer itself or its treatments. It’s a prevalent complication in cancer patients, affecting both the quality of life and the overall management of the disease. Thus, oncology held a significant share of the market in 2022.
“Amongst regions, APAC is expected to witness a higher CAGR during the forecast period”
APAC is expected to grow with a high CAGR in the global erythropoietin stimulating agent market in the forecast period. Several factors such as a surge in the development of a wide range of therapeutics for anemia treatment, enhanced accessibility, and diversified healthcare costs are driving the market’s growth during the forecast period. Further, the increase in incidences of chronic diseases of the kidney and cancer are also having a positive impact on the market’s growth. There have been significant improvisations and enhancements in erythropoietin-stimulating agents in the region. For instance, according to the National Institute of Health in 2022, there were approximately 4,820,000 and 2,370,000 new cancer cases in China. Thus, APAC is expected to witness a higher CAGR during the forecast period.
Erythropoietin Stimulating Agent Market Report Coverage
Reasons to buy this report:
Customization Options:
The global erythropoietin stimulating agent market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to contact us to get a report that completely suits your requirements.
1. Market Introduction
2. Research Methodology Or Assumption
3. Market Synopsis
4. Executive Summary
5. Impact Of Covid-19 On The Erythropoietin Stimulating Agents Market
6. Erythropoietin Stimulating Agents Market Revenue (usd Bn), 2020-2030f
7. Market Insights By Product Type
8. Market Insights By Indication
9. Market Insights By Region
10. Erythropoietin Stimulating Agents Market Dynamics
11. Erythropoietin Stimulating Agents Market Opportunities
12. Erythropoietin Stimulating Agents Market Trends
13. Demand And Supply-side Analysis
14. Value Chain Analysis
15. Competitive Scenario
16. Company Profiled
17. Disclaimer
Research Methodology for the Erythropoietin Stimulating Agents Market Analysis (2023-2030)
Analyzing the historical market, estimating the current market, and forecasting the future market of the global erythropoietin stimulating agent market were the three major steps undertaken to create and analyze the adoption of erythropoietin stimulating agents in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global erythropoietin stimulating agent market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
Detail secondary study was conducted to obtain the historical market size of the erythropoietin stimulating agent market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the erythropoietin stimulating agent market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as product type, indication, and regions. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the erythropoietin stimulating agent market. Further, we conducted factor analysis using dependent and independent variables such as product type, indication, and regions of erythropoietin stimulating agents. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the erythropoietin stimulating agent market sector across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global erythropoietin stimulating agent market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2030 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global erythropoietin stimulating agent market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of product type, indication, and regions in the global erythropoietin stimulating agent market.
The main objective of the Global Erythropoietin Stimulating Agents Market Study
The current & future market trends of the global erythropoietin stimulating agent market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Q1: What is the current market size and growth potential of the erythropoietin stimulating agent market?
Q2: What are the driving factors for the growth of the erythropoietin stimulating agent market?
Q3: Which segment has the largest share of the erythropoietin-stimulating agent market by product type?
Q4: What are the emerging technologies and trends in the erythropoietin stimulating agent market?
Q5: Which region will dominate the erythropoietin-stimulating agent market?
Q6: Who are the key players operating in the erythropoietin-stimulating agent market?
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
